Introduction
CML is a relatively rare myeloproliferative disease believed to originate at the level of the multipotential or 'long-term' hematopoietic stem cell. The defining feature was, until recently, the presence in all leukemia cells of a Philadelphia (Ph) chromosome, but this has now been replaced by identification of a BCR-ABL fusion gene in recognition of the fact that rare patients with a disease indistinguishable from classical CML lack the Ph chromosome, but have a cytogenetically occult BCR-ABL gene. Treatment in the first half of the twentieth century relied predominantly on radiation therapy, but did not demonstrably prolong life beyond a median of 3-5 years. Similarly, busulfan (BU), introduced in the 1950s, and hydroxyurea (hydroxycarbamide, introduced in the 1960s) were most effective as palliation, but prolonged life little if at all. IFN-a, introduced in 1982, was able to produce Ph negativity in a minority of patients and became the treatment of choice for patients ineligible for allo-SCT.
The first SCTs for CML in chronic phase (CP) were performed in Seattle in the late 1970s. The stem cells were obtained from the BMs of their respective genetically identical (syngeneic) twins. 1 The four original patients achieved Ph negativity and remained in good health for the duration of subsequent follow-up. This gave impetus to the notion that patients with CML lacking syngeneic donors might benefit from allo-SCT, and in 1980 transplants using HLA-identical siblings for patients with CML in CP began to be undertaken at specialist centers on both sides of the Atlantic. Twenty years later, the standard recommendation for newly diagnosed patients with CML in CP was to offer allo-SCT as early as possible after diagnosis if the patient was relatively young (for example, less than 50 years of age) and had a suitable donor who would ideally be an HLA-identical sibling but might be a phenotypically HLA-matched family member or a volunteer unrelated donor.
Imatinib mesylate (IM), a tyrosine kinase inhibitor (TKI) that blocks the enzymatic activity of the dysregulated BcrAbl oncoprotein, was introduced into clinical practice in 1998 and by 2000 it was clearly established as being highly effective in inducing complete hematological and cytogenetic remissions in the majority of patients with previously treated CP CML-CP. 2 Although a minority of patients respond relatively poorly to imatinib, the median duration of survival now seems to be much longer than could have been achieved with IFN-a or IFN combined with cytarabine, and some patients may lead apparently normal lives for one or more decades. 3 As a consequence, most new CP patients today are treated initially with imatinib at a dose of 400 mg daily.
Should any new patient receive initial treatment by allo-SCT?
The clinical outcome of allo-SCT for CML can be predicted with some precision. Although morbidity and, indeed, mortality attributable to an allo-SCT may be appreciable, the probability of survival can be predicted with reasonable accuracy by the scoring system developed by Gratwohl et al. on behalf of the European Group for Blood and Marrow Transplantation. 4, 5 Thus, 'good risk' patients with low scores (that is, 0-2), such as those transplanted in CP soon after diagnosis with stem cells collected from an HLA-identical sibling, have a probability of being alive at 5 years after allo-SCT of 60-80%, whereas 'poor risk' patients, such as those transplanted in advanced phase with stem cells from a less well-matched donor, have a much lower chance of long-term survival. For patients who survive at 5 years after allo-SCT, the chance of subsequent relapse, although finite, is low, 6, 7 which means that the majority of long-term survivors may be regarded as operationally 'cured', even if some still harbor in their bodies quiescent leukemia stem cells.
Although imatinib unquestionably prolongs survival for CP CML patients very substantially in comparison with other chemotherapy, its capacity as a single agent to eradicate all residual disease in a given patient remains doubtful. Thus, the clinician and his/her patient has to balance the notion that a transplant, although associated with appreciable risks, can, if successful, cure the leukemia against the knowledge that early results show that IM can clearly prolong life without any definite prospect of 'cure,' and that possible late toxicity cannot yet be reliably predicted. In the event the annual number of transplants performed for CML on both sides of the Atlantic has fallen markedly in the last 5 years, 8, 9 and most hematologists today recommend initial treatment with IM as a single agent or entry into a clinical trial in which IM or another TKI is the initial therapy. A case can be made for offering an up-front transplant to the new patient who is at poor risk according to Sokal's criteria 10 and also at good risk for surviving a transplant by European Group for Blood and Marrow Transplantation criteria mentioned above, 4 but in practice most hematologists would start treatment with IM even for this small sub-group of patients.
There may be three exceptions to this general rule. First, some pediatricians believe that initial treatment by allo-SCT may be the preferred approach for children who have HLA-identical sibling donors, but even this view is giving way to the notion that an initial trial of IM may be preferable. Second, in a situation where the cost of continuing treatment with IM for some considerable number of years is prohibitive, then up-front allografting should be considered, especially if this procedure can be carried out more cheaply than is usual in the western world. Third, there is no doubt that allo-SCT should still be considered as part of the therapeutic strategy for a patient who presents de novo in accelerated phase or blastic transformation. For such patients, treatment along the lines now being developed for the management of Phpositive acute lymphoblastic leukemia may be appropriate. In other words, treatment should begin either with imatinib alone at 600 or 800 mg/day, followed by an appropriate combination of cytotoxic drugs, or alternatively, imatinib may be given simultaneously with cytotoxic drugs. Once Ph-negative status is achieved, a patient should, if possible, proceed to allo-SCT with minimum delay.
How should imatinib failure be defined?
The criteria by which response to imatinib is best defined remain a topic for discussion, but the European LeukemiaNet has recently published proposals. 11 Thus, a CP patient who starts imatinib at a dose of 400 mg daily, should first achieve hematological, then cytogenetic and finally molecular landmarks at given time internals. Failure to achieve the specified landmarks will classify the patient either as a 'failure' or 'sub-optimal' response to imatinib.
Should a patient who has failed imatinib but is still in CP, be offered an SCT or further treatment with a 'second'-generation' TKI?
This was really one of the key questions for 2007. Experience with the principal second-generation TKIs, notably dasatinib and nilotinib, is still limited, but it appears that for patients who do achieve good cytogenetic responses, these are durable. Alternatively, if the patient with IM-resistant leukemia is relatively young and has an HLA-matched donor, the possibility of proceeding to allogeneic SCT should be considered. In the past, delay between diagnosis and allo-SCT has been regarded as an adverse prognostic factor, but this may not apply in the IM era. There is no evidence that prior treatment with IM increases the risk of TRM, 12, 13 but experience is still limited.
Once the decision to proceed with allo-SCT is taken, should one offer a myeloablative or a 'reduced intensity' conditioning transplant?
It is generally believed that a successful allo-SCT may eradicate residual leukemia as a consequence of the combined effects of the chemotherapy or chemoradiotherapy used as 'conditioning' before the transplant, and the GVL effect mediated by immunologically competent cells in the donor inoculum. The concept of the GVL effect provided the rationale for reducing the intensity of the conditioning and exploiting the use of donor-derived T cells to effect cure. Such 'non-myeloablative' or 'reduced-intensity conditioning' transplants should be particularly valuable for patients aged more than 50 years or younger patients with comorbid conditions. One could argue that myeloablative conditioning would be appropriate for a patient in whom disease was in advanced phase, but for a patient in CP, the reduced risk of 100-day mortality might be beneficial.
In the event a number of small single-center series and an analysis of outcome for 186 patients treated in 38 centers reporting to the European Group for Blood and Marrow Transplantation have been published, 14-18 but it is not yet possible to conclude that a reduced-intensity conditioning allo-SCT offers major advantage for the younger patient who would otherwise be a candidate for an allograft with conventional conditioning. Presumably, therefore, study of the use of reduced-intensity conditioning transplants for patients with CML should be continued in the context of formal prospective trials, but other patients should be offered transplants with conventional conditioning.
How should one treat a patient who relapses after allo-SCT for CMP-CP?
The transfusion of lymphocytes collected from the original transplant donor is very effective in restoring complete remission for CML patients who relapse after allo-SCT for CML-CP, although it is somewhat less effective for patients transplanted in advanced phase. The use of donor lymphocyte infusions is associated with a risk of inducing or re-inducing GVHD, but this risk can be minimized if donor lymphocytes are given on an escalating dose schedule. Conversely, imatinib seems to be very effective in restoring complete molecular remission for patients who relapse after allo-SCT, although such remissions are not infrequently lost after the imatinib is discontinued. 19, 20 A reasonable compromise might be to restore remission with imatinib and then to introduce donor lymphocyte infusions starting at a low dose. The effect of reducing or stopping the 'maintenance' imatinib can then be tested at defined intervals.
